| Literature DB >> 33594217 |
Jessica J Lin1,2, Adam Langenbucher1,2, Pranav Gupta1,2, Satoshi Yoda1,2, Isobel J Fetter1,2, Marguerite Rooney1,2, Andrew Do1,2, Marina Kem2,3, Kylie Prutisto Chang1,2, Audris Y Oh1,2, Emily Chin1,2, Dejan Juric1,2, Ryan B Corcoran1,2, Ibiayi Dagogo-Jack1,2, Justin F Gainor1,2, James R Stone2,3, Jochen K Lennerz2,3, Michael S Lawrence1,2, Aaron N Hata1,2, Mari Mino-Kenudson2,3, Alice T Shaw4,5.
Abstract
Histologic transformation from non-small cell to small cell lung cancer has been reported as a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung cancers. Whether small cell transformation occurs in other oncogene-driven lung cancers remains unknown. Here we analyzed the genomic landscape of two pre-mortem and 11 post-mortem metastatic tumors collected from an advanced, ROS1 fusion-positive lung cancer patient, who had received sequential ROS1 inhibitors. Evidence of small cell transformation was observed in all metastatic sites at autopsy, with inactivation of RB1 and TP53, and loss of ROS1 fusion expression. Whole-exome sequencing revealed minimal mutational and copy number heterogeneity, suggestive of "hard" clonal sweep. Patient-derived models generated from autopsy retained features consistent with small cell lung cancer and demonstrated resistance to ROS1 inhibitors. This case supports small cell transformation as a recurring resistance mechanism, and underscores the importance of elucidating its biology to expand therapeutic opportunities.Year: 2020 PMID： 33594217 DOI： 10.1038/s41698-020-0127-9
Source DB: PubMed Journal: NPJ Precis Oncol ISSN： 2397-768X